Prostatic Neoplasms, Castration-Resistant
"Prostatic Neoplasms, Castration-Resistant" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumors or cancer of the PROSTATE which can grow in the presence of low or residual amount of androgen hormones such as TESTOSTERONE.
| Descriptor ID |
D064129
|
| MeSH Number(s) |
C04.588.945.440.770.500 C12.294.260.750.500 C12.294.565.625.500 C12.758.409.750.500
|
| Concept/Terms |
Prostatic Neoplasms, Castration-Resistant- Prostatic Neoplasms, Castration-Resistant
- Castration-Resistant Prostatic Neoplasm
- Neoplasm, Castration-Resistant Prostatic
- Neoplasms, Castration-Resistant Prostatic
- Prostatic Neoplasm, Castration-Resistant
- Prostatic Neoplasms, Castration Resistant
- Androgen-Insensitive Prostatic Neoplasms
- Androgen Insensitive Prostatic Neoplasms
- Androgen-Resistant Prostatic Neoplasms
- Androgen Resistant Prostatic Neoplasms
- Prostatic Neoplasms, Hormone Refractory
- Hormone Refractory Prostatic Neoplasms
- Prostatic Neoplasms, Androgen-Independent
- Androgen-Independent Prostatic Neoplasm
- Neoplasm, Androgen-Independent Prostatic
- Neoplasms, Androgen-Independent Prostatic
- Prostatic Neoplasm, Androgen-Independent
- Prostatic Neoplasms, Androgen Independent
- Prostatic Neoplasms, Androgen-Insensitive
- Androgen-Insensitive Prostatic Neoplasm
- Neoplasm, Androgen-Insensitive Prostatic
- Neoplasms, Androgen-Insensitive Prostatic
- Prostatic Neoplasm, Androgen-Insensitive
- Prostatic Neoplasms, Androgen Insensitive
- Prostatic Neoplasms, Androgen-Resistant
- Androgen-Resistant Prostatic Neoplasm
- Neoplasm, Androgen-Resistant Prostatic
- Neoplasms, Androgen-Resistant Prostatic
- Prostatic Neoplasm, Androgen-Resistant
- Prostatic Neoplasms, Androgen Resistant
- Androgen-Independent Prostatic Neoplasms
- Androgen Independent Prostatic Neoplasms
- Castration-Resistant Prostatic Neoplasms
- Castration Resistant Prostatic Neoplasms
Prostatic Cancer, Castration-Resistant- Prostatic Cancer, Castration-Resistant
- Cancer, Castration-Resistant Prostatic
- Cancers, Castration-Resistant Prostatic
- Castration-Resistant Prostatic Cancers
- Prostatic Cancer, Castration Resistant
- Prostatic Cancers, Castration-Resistant
- Androgen-Insensitive Prostatic Cancer
- Androgen Insensitive Prostatic Cancer
- Androgen-Resistant Prostatic Cancer
- Androgen Resistant Prostatic Cancer
- Prostatic Cancer, Hormone Refractory
- Hormone Refractory Prostatic Cancer
- Prostatic Cancer, Androgen-Independent
- Androgen-Independent Prostatic Cancers
- Cancer, Androgen-Independent Prostatic
- Cancers, Androgen-Independent Prostatic
- Prostatic Cancer, Androgen Independent
- Prostatic Cancers, Androgen-Independent
- Prostatic Cancer, Androgen-Insensitive
- Androgen-Insensitive Prostatic Cancers
- Cancer, Androgen-Insensitive Prostatic
- Cancers, Androgen-Insensitive Prostatic
- Prostatic Cancer, Androgen Insensitive
- Prostatic Cancers, Androgen-Insensitive
- Prostatic Cancer, Androgen-Resistant
- Androgen-Resistant Prostatic Cancers
- Cancer, Androgen-Resistant Prostatic
- Cancers, Androgen-Resistant Prostatic
- Prostatic Cancer, Androgen Resistant
- Prostatic Cancers, Androgen-Resistant
- Androgen-Independent Prostatic Cancer
- Androgen Independent Prostatic Cancer
- Castration-Resistant Prostatic Cancer
- Castration Resistant Prostatic Cancer
|
Below are MeSH descriptors whose meaning is more general than "Prostatic Neoplasms, Castration-Resistant".
Below are MeSH descriptors whose meaning is more specific than "Prostatic Neoplasms, Castration-Resistant".
This graph shows the total number of publications written about "Prostatic Neoplasms, Castration-Resistant" by people in this website by year, and whether "Prostatic Neoplasms, Castration-Resistant" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2013 | 2 | 0 | 2 |
| 2014 | 1 | 0 | 1 |
| 2015 | 2 | 0 | 2 |
| 2016 | 3 | 0 | 3 |
| 2017 | 2 | 0 | 2 |
| 2018 | 3 | 2 | 5 |
| 2019 | 4 | 0 | 4 |
| 2020 | 3 | 1 | 4 |
| 2021 | 7 | 0 | 7 |
| 2022 | 4 | 0 | 4 |
| 2023 | 6 | 0 | 6 |
| 2024 | 2 | 1 | 3 |
| 2025 | 5 | 0 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Prostatic Neoplasms, Castration-Resistant" by people in Profiles.
-
Leptin levels are associated with coronary artery calcification in patients with advanced prostate cancer. Oncologist. 2025 Aug 04; 30(8).
-
Real-world trends in the use and outcomes of novel androgen receptor signaling inhibitor therapy in patients with non-metastatic castration-resistant prostate cancer: a multicenter retrospective study. Int J Clin Oncol. 2025 Sep; 30(9):1858-1865.
-
Functional assessment in patients with castration-resistant prostate cancer treated with darolutamide: results from the DaroAcT study. Oncologist. 2025 Jul 04; 30(7).
-
Cholesterol metabolism regulated by CAMKK2-CREB signaling promotes castration-resistant prostate cancer. Cell Rep. 2025 Jun 24; 44(6):115792.
-
Real-world effectiveness of darolutamide in metastatic castration-resistant prostate cancer. Endocr Relat Cancer. 2025 Jun 01; 32(6).
-
PARP inhibitor response is enhanced in prostate cancer when XRCC1 expression is reduced. NAR Cancer. 2025 Jun; 7(2):zcaf015.
-
PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial. Nat Commun. 2024 12 30; 15(1):10743.
-
Castration-resistant prostate cancer is resensitized to androgen deprivation by autophagy-dependent apoptosis induced by blocking SKP2. Sci Signal. 2024 12 17; 17(867):eadk4122.
-
The role of Cabazitaxel in Patients With Castration-Resistant and Osseous Metastases Prostate Cancer. A Hellenic Cooperative Oncology Group Phase II Study: Cabazitaxel in mCRPC patients with osseous metastases. Clin Genitourin Cancer. 2025 Feb; 23(1):102253.
-
Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer. JAMA Netw Open. 2024 10 01; 7(10):e2437871.